Cesca Therapeutics Inc(NASDAQ:KOOL) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during After-hours on Nov 17, 2016. Company reported revenue of $3.77M. Analysts estimated a revenue of $4.41M. The revenues were $-643.00K or NaN% below the estimates. Earnings per share were $-2.29.
Cesca Therapeutics Inc (KOOL) shares turned negative on Mondays trading session with the shares closing down -0.18 points or -5.31% at a volume of 1,27,493. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $3.7. The peak price level was also seen at $3.7 while the days lowest was $3.07. Finally the shares closed at $3.21. The 52-week high of the shares is $9.2 while the 52-week low is $1.638. According to the latest information available, the market cap of the company is $31 M.
Several Insider Transactions has been reported to the SEC. On Sep 4, 2015, Matthew T Plavan (Former CEO) sold 17,271 shares at $0.68 per share price.
Cesca Therapeutics Inc. is focused on the research development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients physicians and partners: cellular therapeutics medical/diagnostic device development and commercialization and cell manufacturing and banking. The Company focuses on three areas: critical limb ischemia (CLI) acute myocardial infarction (AMI) and bone marrow transplant (BMT). The Company offers SurgWerks and VXP System Platform and CellWerks Platform. Its products include AutoXpress (AXP) System MarrowXpress (MXP) System BioArchive System and Res-Q 60 BMC. It also provides cell manufacturing and banking services.